BRAF and melanoma: It was demonstrated that β-carotene alone (1 μM) did not affect BRAF or ERK expression in melanoma cell lines carrying the B-RAF mutation (A2058 cell line), while in combination with B-RAFi (PLX), it enhanced the suppression of B-RAF activation and of the downstream Erk1/2 effector, induced by PLX [92], suggesting its potential use as an adjuvant for target-based therapy.